UCB finds positive results in late-stage study evaluating arthritis treatment
Monday, June 15, 2015
Ucb Sa Positive results from phase 3 study evaluating Cimzia(Certolizumab Pegol) in DMARD-naïve rheumatoid arthritis patients.
Phase 3 C-EARLY study showed substantial benefits, at 52 weeks, of adding Cimzia to optimized methotrexate treatment.
Submitted regulatory application to EMA for an extension of Cimzia indication in RA.
reuters.com
